**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ASH VPS US | **Project Code** | PI4VPO107 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey/Briana B |
| **Compliance** | Briana Devaser | **Editor** | Heather/Christi |

**Launch Date/Internal Launch Date:**

**Friday, December 5**

**Project Type**

Video

Downloadable Slides

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**Webcast/PDS URL:**

**www.primeoncology.org/sanfrancisco\_vp\_us**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: 2014 VPS US SF**

**Listing Page**

**[Insert small VPS US Graphic to the left]**

**[TITLE]**

Virtual Poster Session: Clinical Implications and Optimal Application of Emerging Data From   
the 2014 Annual Hematology Meeting in San Francisco

**[DATE** | **LOCATION]**

December 2014| San Francisco, California

**Landing Page**

**[Insert VPS US Graphic header]**

**LEFT SIDE**

**[Insert Text below]**

Virtual Poster Session: Clinical Implications and Optimal Application of Emerging Data From   
the 2014 Annual Hematology Meeting in San Francisco

**Activity Features**

**[Insert icon]** Interactive Presentation

**[Insert icon]** Downloadable Slides

**[Insert icon]** CME-Certified

**RIGHT SIDE**

**ACTIVITY OVERVIEW**

View CME-certified abstract presentations and downloadable slides from the 2014 Annual Hematology Meeting in San Francisco.

**CONTINUING EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credit(s)™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**BOTTOM MIDDLE**

**[Insert List of Disease Type Tabs…as many as needed]**

* **Chronic Leukemia**
* **Multiple Myeloma**
* **Myeloproliferative Neoplasms**

**[Tab-Leukemia]**

Chronic Leukemia

[Insert Screen Shot] **Abstract #152:** Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

*Presented by: Jorge Cortes, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #327:** Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results From the Phase II RESONATE™-17 Trial

*Presented by: Susan O’Brien, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #330:** Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

*Presented by: Jeff Sharman, MD*

[Button to the right of the abstract listing] View

**[Insert divider line]**

[Insert Screen Shot] **Abstract #519:** EPIC: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

*Presented by: Jeffrey Lipton, MD, PhD, FRCPC*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #4532:** Deep Molecular Response to Nilotinib as First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party

*Presented by: Fausto Castagnetti, MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #\_\_\_:** TBD

*Presented by: TBD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

**[Tab-MM]**

**Multiple Myeloma**

[Insert Screen Shot] **Abstract #31:** Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

*Presented by: Ravi Vij, MBBS, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #32:** Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients With Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

*Presented by: Jonathan Kaufman, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #33:** Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy With Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

*Presented by: Jatin Shah, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

*Presented by: A. Keith Stewart, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

*Presented by: Shaji Kumar, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #175:** Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

*Presented by: Antonio Palumbo, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #198:** Impact of Autologous Transplantation vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

*Presented by: Francesca Gay, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #4742:** Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

*Presented by: Jesus San Miguel, MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

**[Tab-MPN]**

Myeloproliferative Neoplasms

[Insert Screen Shot] **Abstract #320:** Reduced Intensity vs. Standard Conditioning Followed by Allogeneic Stem Cell Transplantation for Patients With MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

*Presented by: Nicolaus Kröger, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot **Abstract #405:** Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

*Presented by: Alessandro Vannucchi, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #709:** Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

*Presented with: Ruben Mesa, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #711:** Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients With Intermediate or High-Risk Myelofibrosis

*Presented by: Jean-Jacques Kiladjian, MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #1860:** The Prognostic Impact of the Mutational Profile in Patients With Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

*Presented by: Dietger Niederwieser, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #\_\_\_:** TBD

*Presented by: TBD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

**CME Information Pop-Up**

**Release Date**   
December 5, 2014  
  
**Expiration Date**   
December 5, 2015

**Faculty  
Fausto Castagnetti, MD, PhD**

Bologna University School of Medicine

Bologna, Italy

**Jorge Cortes, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**Francesca Gay, MD**

University of Torino

Torino, Italy

**Jonathan Kaufman, MD**

Winship Cancer Institute

Emory University

Atlanta, Georgia, United States

**Jean-Jacques Kiladjian, MD, PhD**

Hôpital Saint-Louis & Université Paris Diderot

Paris, France

**Nicolaus Kröger, MD**

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

**Shaji Kumar, MD**

Mayo Clinic

Rochester, Minnesota, United States

**Jeffrey Lipton, MD, PhD, FRCPC**

Princess Margaret Cancer Centre

University of Toronto

Toronto, Ontario, Canada

**Ruben Mesa, MD**

Mayo Clinic Cancer Center

Scottsdale, Arizona, United States

**Dietger Niederwieser, MD**

University of Leipzig

Leipzig, Germany

**Susan O’Brien, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**Antonio Palumbo, MD**

University of Torino

Torino, Italy

**Jesus San Miguel, MD, PhD**

Universidad de Navarra

Pamplona, Spain

**Jatin Shah, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**Jeff Sharman, MD**

Willamette Valley Cancer Institute/US Oncology Research

Springfield, Oregon, United States

**A. Keith Stewart, MD**

Mayo Clinic

Scottsdale, Arizona, United States

**Alessandro Vannucchi, MD**

University of Florence

Florence, Italy

**Ravi Vij, MBBS, MD**

Washington University School of Medicine

Saint Louis, Missouri, United States

**TBD**

TBD

TBD

**TBD**

TBD

TBD

**Learning Objectives**  
After successful completion of this educational activity, participants should be able to:

* Evaluate recent findings from studies investigating biomarkers and molecular features of hematologic malignancies and disorders
* Apply emerging data from clinical trials evaluating novel agents and treatment approaches for hematologic malignancies and disorders
* Identify appropriate clinical trials and refer eligible patients with hematologic malignancies and disorders for enrollment to expand their treatment options

**PROVIDER  
This activity is provided by prIME Oncology.**

**Support**   
Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Target Audience**   
This educational activity is specifically designed for practicing hematologists; medical, surgical, and radiation oncologists; and other healthcare professionals interested in and/or involved in the treatment of patients with cancer in the United States.

**Continuing Medical Education**  
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credits****™****.* Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Method of Participation**  
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx).   
  
A link to the posttest is available on the video player pages.

In order to claim credit for this activity, a score of XX% or higher is required.

**Disclosure of Conflicts of Interest**  
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

**Faculty Disclosures**  
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Castagnetti has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cortes has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gay has \_\_\_\_\_\_\_. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Kaufman has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kiladjian has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kröger has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kumar has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lipton has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mesa has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Niederwieser has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Brien has \_\_\_\_\_\_\_. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Palumbo has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr San Miguel has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shah has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sharman has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vannucchi has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vij has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Janice Galleshaw, MD (medical content reviewer/planner) – no relevant financial relationships
* Chelsey Goins, PhD (clinical content reviewer/planner) – no relevant financial relationships
* Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

**Disclosure Regarding Unlabeled Use**  
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**  
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



**Player Page (Chronic Leukemia-Cortes)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #152:** Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

*Presented by: Jorge Cortes, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper68183.html]**

**FEATURED EXPERTS**

**Jorge Cortes, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Chronic Leukemia-O’Brien)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #327:** Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results From the Phase II RESONATE™-17 Trial

*Presented by: Susan O’Brien, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper67778.html]**

**FEATURED EXPERTS**

**Susan O’Brien, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Chronic Leukemia-Sharman)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #330:** Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

*Presented by: Jeff Sharman, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper75533.html]**

**FEATURED EXPERTS**

**Jeff Sharman, MD**

Willamette Valley Cancer Institute/US Oncology Research

Springfield, Oregon, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Chronic Leukemia-Lipton)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #519:** EPIC: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

*Presented by: Jeffrey Lipton, MD, PhD, FRCPC*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70542.html]**

**FEATURED EXPERTS**

**Jeffrey Lipton, MD, PhD, FRCPC**

Princess Margaret Cancer Centre

University of Toronto

Toronto, Ontario, Canada

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Chronic Leukemia-** **Castagnetti)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #4532:** Deep Molecular Response to Nilotinib as First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party

*Presented by: Fausto Castagnetti, MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper72851.html]**

**FEATURED EXPERTS**

**Fausto Castagnetti, MD, PhD**

Bologna University School of Medicine

Bologna, Italy

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Chronic Leukemia-TBD)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #\_\_\_:** TBD

*Presented by: TBD*

**Click here to view abstract [http://TBD]**

**FEATURED EXPERTS**

TBD

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Multiple Myeloma-VIj)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #31:** Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

*Presented by: Ravi Vij, MBBS, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper67777.html]**

**FEATURED EXPERTS**

**Ravi Vij, MBBS, MD**

Washington University School of Medicine

Saint Louis, Missouri, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Multiple Myeloma-Kaufman)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #32:** Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients With Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

*Presented by: Jonathan Kaufman, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70568.html**

**FEATURED EXPERTS**

**Jonathan Kaufman, MD**

Winship Cancer Institute

Emory University

Atlanta, Georgia, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Multiple Myeloma-Shah)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #33:** Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy With Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

*Presented by: Jatin Shah, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper76502.html]**

**FEATURED EXPERTS**

**Jatin Shah, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Multiple Myeloma-Stewart)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

*Presented by: A. Keith Stewart, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70771.html]**

**FEATURED EXPERTS**

**A. Keith Stewart, MD**

Mayo Clinic

Scottsdale, Arizona, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Mulitple Myeloma-Kumar)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

*Presented by: Shaji Kumar, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69951.html]**

**FEATURED EXPERTS**

**Shaji Kumar, MD**

Mayo Clinic

Rochester, Minnesota, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Multiple Myeloma-Palumbo)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #175:** Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

*Presented by: Antonio Palumbo, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper68244.html]**

**FEATURED EXPERTS**

**Antonio Palumbo, MD**

University of Torino

Torino, Italy

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Mulitple Myeloma-Gay)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #198:** Impact of Autologous Transplantation vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

*Presented by: Francesca Gay, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper68373.html]**

**FEATURED EXPERTS**

**Francesca Gay, MD**

University of Torino

Torino, Italy

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (Multiple Myeloma-San Miguel)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #4742:** Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

*Presented by: Jesus San Miguel, MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69254.html]**

**FEATURED EXPERTS**

**Jesus San Miguel, MD, PhD**

Universidad de Navarra

Pamplona, Spain

**SUPPORT STATEMENT**

**Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.**

**Player Page (MPN-** **Kröger)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #320:** Reduced Intensity vs. Standard Conditioning Followed by Allogeneic Stem Cell Transplantation for Patients With MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

*Presented by: Nicolaus Kröger, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper72696.html]**

**FEATURED EXPERTS**

**Nicolaus Kröger, MD**

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (MPN-Vannucchi)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #405:** Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

*Presented by: Alessandro Vannucchi, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70459.html]**

**FEATURED EXPERTS**

**Alessandro Vannucchi, MD**

University of Florence

Florence, Italy

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (MPN-Mesa)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #709:** Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

*Presented with: Ruben Mesa, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69746.html]**

**FEATURED EXPERTS**

**Ruben Mesa, MD**

Mayo Clinic Cancer Center

Scottsdale, Arizona, United States

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (MPN-Kiladjian)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #711:** Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients With Intermediate or High-Risk Myelofibrosis

*Presented by: Jean-Jacques Kiladjian, MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper66844.html]**

**FEATURED EXPERTS**

**Jean-Jacques Kiladjian, MD, PhD**

Hôpital Saint-Louis & Université Paris Diderot

Paris, France

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (MPN-Niederwieser)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #1860:** The Prognostic Impact of the Mutational Profile in Patients With Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

*Presented by: Dietger Niederwieser, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper73185.html]**

**FEATURED EXPERTS**

**Dietger Niederwieser, MD**

University of Leipzig

Leipzig, Germany

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Player Page (MPN-TBD)**

**[Insert VPS US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

**Abstract #\_\_\_\_: TBD**

*Presented by: TBD*

**Click here to view abstract [http:// TBD]**

**FEATURED EXPERTS**

**TBD**

**SUPPORT STATEMENT**

Support for this educational activity is provided by Onyx Pharmaceuticals, Inc. and Pharmacyclics.

**Evaluation and Credit Request Planstone Link: Will be provided shortly prior to launch.**